Novo Nordisk receives approval in the EU for use of NovoRapid® in elderly people

Novo NordiskNovo Nordisk today announced that the European Commission has approved the rapid-acting insulin NovoRapid® (insulin aspart) for treatment of diabetes in the elderly and in people with renal or hepatic impairment.

NovoRapid® has been available since 1999 and is to date the only rapid-acting, modern insulin to receive such an approval for use in elderly people. With this, NovoRapid® has been established as an insulin that is safe to use by all people from two years of age with types 1 or 2 diabetes[1].

"Diabetes is a progressive disease and as such, many older people with diabetes are requiring more intensive insulin therapy as time goes by," says Dr Tim Heise, MD, CEO – Clinical Science, one of the leading authors of the trials behind the approval.

"The trials we conducted in 2001 and 2002 showed that insulin aspart is absorbed rapidly and reaches peak activity in a short time in the elderly population[2], which should allow for a flexible treatment with improved meal-time coverage[3]. The new approval of insulin aspart provides a new treatment option for those patients who have difficulties in maintaining acceptable blood glucose levels around mealtimes with their current human insulin treatment," adds Dr Heise.

According to the International Diabetes Federation (IDF), approximately 20% of the world’s elderly population live with diabetes, and the figure is steadily increasing. Many older people with diabetes currently use human insulin, but with the efficacy and safety of NovoRapid® now documented specifically in the elderly, this presents a new and improved treatment option.

About NovoRapid®
NovoRapid® (insulin aspart) is a rapid-acting modern insulin, licensed in the EU for the treatment of type 1 and type 2 diabetes in children aged two years or older[4], pregnant women[5],[6], elderly2 and special populations with renal and hepatic impairment[7].

NovoRapid® can be injected immediately before or soon after a meal3 and is normally used in a basal/bolus combination regimen with a long-acting insulin such as Levemir® (insulin detemir).

NovoRapid® has a faster onset and shorter duration of action than soluble human insulin. It offers significant improvements in glucose control after a meal[8],[9] with significantly less incidence of nocturnal hypoglycaemia[10].

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,350 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

References
[1] Summary of Product Characteristics, NovoRapid®, September 2007.
[2] Krones R, et al. Time-action profiles of insulin aspart and human regular insulin in elderly and middle-aged subjects with Type 2 diabetes. Diabetologia 2004; 47 (Suppl 1):A266.
[3] Rosenfalck AM, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37:41–6.
[4] Mortensen HB, et al. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159:483–8.
[5] Hod, M, et al. Fetal and Perinatal Outcomes in Type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obs Gyn 2007 (in press).
[6] Mathiesen ER et al. Maternal Glycemic Control and Hypoglycaemia in Type 1 Diabetic Pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30:771–776.
[7] Holmes, G et al. Pharmcokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60:469–76.
[8] Brunner GA, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17:371–375.
[9] Danne T, et al. A comparison of Postprandial and Pre-prandial Administration of Insulin Aspart in Children and Adolescents With Type 1 Diabetes. Diabetes Care 2003; 26:2359–2384.
[10] Heller S, et al. Hypoglycaemia with insulin aspart: a double blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21:769–775.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...